The United States spends more on healthcare than any other country, yet the reasons aren’t what most people assume. It’s not that Americans use more medical services. For most procedures, Americans actually visit the doctor less and spend fewer days in the hospital than people in peer nations. The difference comes down to price: every component of the system, from drugs to doctor visits to administrative paperwork, costs dramatically more in the U.S. than anywhere else.
Higher Prices, Not More Care
A common misconception is that Americans are overusing the healthcare system. In reality, of twelve common services studied by the Peterson-KFF Health System Tracker, Americans used only three (cesarean sections, CT scans, and coronary bypass surgeries) at rates higher than peer nations. Yet costs for all twelve services were consistently higher in the U.S., across both private and public insurance.
The gap between private insurance and public programs like Medicare tells a revealing story. An outpatient knee MRI costs about $165 through Medicare, roughly in line with the $143 average across comparable countries. But the same MRI billed to a private insurer costs $566, more than three times the Medicare price. A CT scan shows the same pattern: $167 through Medicare, $553 through private insurance, compared to $132 in peer nations. A cesarean section through private insurance runs about $13,601, compared to $5,928 in comparable countries. These aren’t different procedures. They’re the same scans and surgeries, just billed at wildly different rates.
Drug Prices Dwarf the Rest of the World
Brand-name prescription drugs in the U.S. cost 422 percent of prices in other high-income countries, according to a 2022 analysis published in the RAND Health Quarterly. Even after adjusting for the rebates drug companies pay to insurers and pharmacy benefit managers, U.S. brand-name drug prices still land at 308 percent of international prices. That means Americans pay roughly three to four times what people in other wealthy nations pay for the same medications.
Part of the explanation is that most other countries negotiate drug prices at a national level, setting caps on what manufacturers can charge. The U.S. has historically left pricing to the market, giving pharmaceutical companies significant leverage. The industry has also spent heavily on marketing. In 2004, the pharmaceutical industry spent $57.5 billion on promotion in the U.S. versus $31.5 billion on research and development. Among the top 100 pharmaceutical companies by sales in 2015, 64 spent twice as much on marketing as on R&D, and 27 spent ten times as much.
Administrative Costs Are Unmatched
Between 15 and 30 percent of all U.S. medical spending goes to administration: billing, coding, insurance processing, prior authorizations, and compliance paperwork. The U.S. spends $1,055 per person per year on administrative costs alone. Germany, the next highest spender among wealthy nations, spends $306 per capita. That gap reflects the complexity of operating in a system with hundreds of private insurers, each with different rules, coverage networks, forms, and approval processes.
Hospitals and doctors’ offices employ large billing departments to navigate this patchwork. The Affordable Care Act requires private insurers to spend at least 80 to 85 percent of premium revenue on actual medical care, capping administrative overhead and profit at 15 to 20 percent. But that still leaves a substantial slice of every premium dollar going to something other than your care, and the compliance infrastructure on the provider side adds further cost that patients ultimately absorb.
Doctors Earn More, and It’s Not Close
American physicians earn an average of $316,000 per year. In Germany, that figure is $183,000. In the United Kingdom, $138,000. In France, $98,000. These salary differences are partly driven by the high cost of medical education in the U.S., where new doctors often graduate with hundreds of thousands of dollars in student debt, creating pressure for higher compensation. But the gap also reflects a market where physician groups and hospital systems have growing negotiating power with insurers, pushing reimbursement rates upward.
Hospital Consolidation Drives Prices Up
Over the past two decades, hospitals and physician practices have been steadily merging into larger health systems. When a hospital system dominates a region, it can demand higher prices from insurers because there’s no meaningful alternative. A U.S. Government Accountability Office review found that when physician practices consolidate with hospitals, services previously delivered in lower-cost office settings shift to more expensive hospital-based settings, driving up both Medicare spending and commercial insurance prices.
This consolidation also affects competition. In many parts of the country, a single health system controls most of the hospital beds and specialist practices. Insurers that want to offer a network in that area have little choice but to accept the system’s prices, and those costs flow directly into the premiums you pay.
Chronic Disease Consumes 86 Percent of Spending
About half of all Americans live with at least one chronic condition, such as diabetes, heart disease, or obesity. Treating these ongoing conditions accounts for 86 percent of total U.S. healthcare spending. This isn’t unique to the U.S. in concept, but the scale is striking. High rates of obesity, diabetes, and heart disease create a constant demand for medications, specialist visits, hospitalizations, and long-term management that compounds every other cost driver in the system.
Because chronic diseases require sustained treatment rather than one-time interventions, they interact with every inflated price point. A patient managing diabetes for decades is affected by high drug prices, frequent specialist visits billed at U.S. rates, and administrative friction at every encounter. The chronic disease burden doesn’t just add to spending; it multiplies the impact of all the other factors making care expensive.
Defensive Medicine and Malpractice Fear
Doctors in the U.S. practice in one of the most litigious medical environments in the world, and that shapes how they order tests. Defensive medicine, the practice of ordering tests or procedures primarily to protect against potential lawsuits rather than for clinical necessity, costs an estimated $46 billion annually. One study across three hospital medicine services found that 28 percent of orders were judged to be at least partially defensive, accounting for about 13 percent of costs per patient. Only about 3 percent of costs were entirely defensive, meaning the test had no clinical rationale at all. Most defensive spending falls in a gray zone where the test has some value but wouldn’t have been ordered if malpractice risk weren’t a factor.
Price Transparency Remains Weak
Federal rules now require hospitals to publicly post their prices, but compliance has been slow. A 2024 audit by the HHS Office of Inspector General found that an estimated 46 percent of the roughly 5,900 hospitals subject to the price transparency rule were not fully complying. Without accessible pricing information, patients and employers can’t comparison shop, and the competitive pressure that might otherwise push prices down simply doesn’t exist in most markets.
This opacity benefits the most expensive players in the system. When you can’t see what a procedure costs before you agree to it, and when your insurance company negotiates rates behind closed doors, there’s little incentive for any party to lower prices. The result is a system where costs are high not because of any single villain, but because every layer, from drugs to doctor pay to billing departments to hospital monopolies, operates without the pricing discipline found in nearly every other industry or healthcare system worldwide.